Summary.-Prostaglandin (PG) E2 biosynthesis in Yoshida hepatoma (AH 130) was evaluated by radioimmunoassay. When hepatoma cells were incubated in vitro, the levels of PGE2 in the medium were similar to those found in hepatocytes for the first 2 h; this was followed by a rapid increase in PGE2 formation, and the 6h incubation levels were 4-fold higher than in hepatocytes.
BY SHOWING RAISED LEVELS of prostaglandins (PGs) in tumours and plasma of tumour-bearing patients, Karim (1976) opened up the way to studies which have extended these findings to several human and animal tumours. In addition, using cultured cells, it has been found that transformation by carcinogens or by viruses (Hammarstrom, 1977) is followed by increased production of PGs.
It is difficult to correlate these findings with claims that PGs inhibit tumour growth in vitro or in vivo (Santoro et al., 1976) . On the other hand, Plescia et al. (1975) have suggested that PGs may be used by tumours to subvert the immune system. This hypothesis also accords with the marked sensitivity of lymphocytes as well as macrophages to PGE which, by increasing cyclic AMP levels, antagonizes mitogen-induced cell proliferation or cytotoxicity (Pelus & Strausser, 1977; Schultz et al., 1978) .
The results reported here indicate that the rapidly growing cells of Yoshida hepatoma produce considerable amounts of PGE2 (4-fold more than rat hepatocytes) and that indomethacin or acetylsalicylic acid strongly reduce the growth of the tumour in vivo and very significantly prolong the survival of tumour-bearing rats. Thus, increased PGE2 production seems positively correlated with tumour growth.
MATERIALS AND METHODS
Materials.-3H-prostaglandin E2 (sp. act. 160 Ci/mmol), G-3H-adenosine 3', ,ug/ml). After centrifugation supernates were acidified to pH 3-5 with 2N formic acid and PGs were extracted twice with 5 vols ethyl acetate (recovery >95%). The extracts were taken to dryness and PGE was purified by column chromatography using CHC13/ CH30H mixtures as described by Salmon & Karim (1975) with a recovery 75%. Radioimmunoassay was carried out as previously described were placed in an ice bath and 100 ,u of freshly prepared albumin-coated charcoal suspension (100 mg/ml 3% bovine serum albumin in Tris-HCl 0-05M, pH 7.5) was quickly added and the tubes were vortexed for 30 s. After standing in ice for 5 min, they were centrifuged at 2000 g for 5 min. 0-2ml supernates were counted with 4 ml of Bray solution. Cross-reactivities were as reported elsewhere . In addition, 6-keto-PGF1, cross-reacted 3.5% and TxB2 0-01 %. The method has a sensitivity of 3 pg, an accuracy (recovery of PGE2 added to buffer) >90% and intra-or inter-assay coefficients of variations < 10%.
PGJ2 was assayed by the platelet aggregation test, as previously described . Aliquots (50 ,ul) of washed hepatoma cells (10-20 mg protein per ml of buffer) were pre-incubated for 5 min with 0.5 ml human platelet-rich plasma (PRP) and aggregation was induced with 1 5mM Na arachidonate. In other experiments cells were incubated with 0-1mM Na arachidonate for 10 min at 37TC, cells were removed by centrifugation and aliquots of the supernatant solutions were immediately added to 0.5 ml of PRP. Aggregation was induced 2 min later as described above. Cyclic AMP was measured by the method of Brown et al. (1971) . Proteins were determined by the Lowry method, using bovine serum albumin as standard.
Cell counts were performed on a Model ZBI Coulter Counter (Coulter Electronics, Hialeah, FL.) equipped with a 100pM aperture and a 0-5ml manometer. Yoshida hepatoma cells were counted at settings of 1/amplification = 16 and 1 /aperture current = 1/2 with a window of 15-100. The data are usually the mean of 3 observations. The data in Fig. 3 at 37°C for 2-5-360 min and the release of PGE2 into the medium was evaluated by radioimmunoassay.
In Fig. 1 it is shown that a slow increase in PGE2 production was followed after 120 min by a rapid increase in the rate of synthesis; even after 360 min incubation the curve failed to reach a plateau. This is in marked contrast to the results using hepatocytes in which PGE2 production levels off at 60 min and the levels remain even after a 4h incubation (not shown) at least 4-fold lower than those in tumour cells.
In addition, during incubation cyclic AMP levels were determined (Fig. 1) that liver sinusoidal cells were capable, in similar experimental conditions, of inhibiting arachidonate-induced aggregation.
The effect of non-steroidal anti-inflammatory drugs on the growth rate In Fig. 2 tion of its formation; (b) TxB2 crossreacts very little (<0-01%) with our antibodies. These data prompted us to test its effect on tumour growth rate in vivo. Two groups of rats were injected with tumour cells and tumour cells plus indomethacin (1 mg/ kg body wt) respectively. The drug was then administered twice a day and rats were killed 4-11 days after tumour implants. In Fig. 3 it is shown that in rats injected with indomethacin there was a dramatic reduction in the total number of tumour cells as evaluated by a Coulter Counter, both during the exponential and stationary phases of growth.
To establish whether growth rate is slowed down or proliferation blocked after indomethacin treatment requires a different experimental approach. That this effect of indomethacin is very probably connected with its ability to inhibit PG biosynthesis is supported by experiments showing that acetylsalicylic acid has an effect very like that of indomethacin. This drug, injected i.p. at a dose of 10-0 mg/kg body wt once a day, appears markedly to inhibit tumour mass, at least at the 7th day after tumour implan- tation (not shown). This low dose is probably effective because it is acting directly on the hepatoma cells in the peritoneal cavity.
Further and more direct evidence was obtained by injecting i.p. PGE2 (1 mg/kg) into tumour-bearing, indomethacintreated rats. It was found (Fig. 4) that PGE2 was capable of counteracting the inhibition of growth due to the drug, making the growth rate indistinguishable from the controls.
In the As far as the significance of this high production of PGs in tumours is concerned, two hypotheses have been more or less explicitly proposed. Thomas et al. (1974) , after establishing the existence of an inverse relationship between rates of cell proliferation and PGE biosynthesis, suggested that PGE may be directly involved in the inhibition of tumour-cell growth (Santoro et al., 1976) . Tumour-growth inhibition by a synthetic analogue of PGE2 has been observed (Santoro & Jaffe, 1979) (Tomasi et al., 1974) .
We consider more likely the hypothesis proposed by Plescia et al. (1975) Tomasi et al., 1978 Tomasi et al., , 1979 Tomasi, 1976 (Pelus & Strausser, 1977; Schultz et al., 1978 (Karim, 1976) . At present it is difficult
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In most studies showing raised PG levels in tumours, indomethacin or aspirin have been tested as anti-tumour drugs, and in several cases they proved extremely effective. Thus, indomethacin has been shown both to decrease plasma or urinary levels of PGs and to restore normal blood calcium levels both in patients with solid tumours and hypercalcemia (Seyberth et al., 1975; Robertson et al., 1976) and in hypercalcaemic mice bearing a prostaglandin-producing fibrosarcoma (Tashjian et al., 1973) . Immunosuppressive mouse tumours treated in vivo or in vitro with non-steroidal anti-inflammatory drugs lost their capacity to suppress antibody production (Plescia et al., 1975; Grinwich & Plescia, 1977) .
Our data clearly show that indomethacin or acetylsalicylic acid at low doses markedly inhibit cell proliferation in vivo, an effect which is paralleled by the in vitro inhibition of PGE2 biosynthesis. However, we are aware that this correlation has to be considered cautiously, since so many effects of anti-inflammatory drugs apparently unrelated to prostaglandin synthesis have been reported (Flower, 1974; Kantor & Hampton, 1978) .
In this respect, the experiments reported in Fig. 4 , indicating that injections of PGE2 overcome indomethacin inhibition, strongly suggest that inhibition of PG synthesis and decrease of growth rate are two closely associated events. Unfortunately the most direct approach to this problem (i.e. the use of PGE2 antagonists) is hampered by the lack of potency and specificity of the available compounds.
Since PGE2 is well known to have a short life in the circulation, its action may be exerted on lymphocytes or macrophages of the peritoneal cavity. Alternatively, a circulating metabolite of PGE2 with some biological activity may be involved in these effects.
Our data showing that indomethacin very significantly prolongs survival of tumour-bearing rats, as well as similar data recently reported (Lynch & Salomon, 1979; Bennett et al., 1979) are forcing into consideration the use of PG synthetase inhibitors in the combined therapeutic approach to the treatment of some tumours, especially since indomethacin has been reported to be non-immunosuppressive like other types of antiinflammatory drug (Plescia et al., 1975) .
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